Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Jinhua chain pharmacy big "physical examination" peak pharmacy got an "A"
Jinhua City Market Supervision Bureau recently announced the results of drug quality credit rating of drug retail chain enterprises in the city, and Jianfeng Pharmacy was rated as A in this "physical examination. According to the spirit of the document "Implementation Plan for Drug Quality Credit Classification Management of Jinhua Drug Trading Enterprises" and in accordance with relevant evaluation standards, Jinhua Market Supervision Bureau evaluated the 2019 drug quality credit rating of 34 drug retail chain enterprises (headquarters) in the city that met the evaluation requirements, involving 1498 stores. The score combines the daily supervision and inspection of chain headquarters, GSP certification inspection, administrative punishment and other drug quality-related information with the credit rating results of subordinate stores, and divides 100 into basic points, and forms the final score after adding and subtracting points according to the evaluation system. Those with 93 points or above are grade A (trustworthy enterprises),85-92 are grade B (basically trustworthy enterprises), and 80-84 are grade C (slightly dishonest enterprises), A score below 80 is Grade D (seriously dishonest enterprise). It is understood that the market supervision department will enter the enterprise credit rating evaluation results into the drug safety credit management system of Zhejiang Food and Drug Administration and Jinhua intelligent supervision and supervision platform to establish enterprise credit files. According to the credit rating evaluation results over the years, classified management will be carried out, and low-grade enterprises will increase the frequency of inspection. The "credit rating publicity board of drug trading enterprises" will be hung in the retail drugstore hall, and the evaluation results of the store will be publicized every year, let the people intuitively understand the credit situation of the store. At the same time, A- level enterprises are also the threshold for obtaining the qualification of designated medical insurance units, all kinds
2020
07-31
Daye Mayor to Daye Peak Research Issued "Anti-Epidemic" Donation Certificate
On the morning of March 26, Daye City Deputy Secretary, Mayor Zhou Jun and Daye City Economic and Information Bureau, Security Town and other responsible persons visited Daye Peak Cement Company to understand the epidemic prevention and control and resumption of production, and on behalf of the Daye City Charity Federation issued a certificate of donation of epidemic prevention and control materials. Accompanied by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Peak, Yuan Xianming, executive deputy general manager of Daye Peak, and others, Zhou Jun and his entourage went to the work site of Daye Peak to learn about the resumption of work and production. Zhang Fengliang introduced the progress of the upgrading and transformation of the grate cooler, the transformation of the kiln cylinder and the technical transformation of the cement mill system, and made a detailed report on the production and technical transformation organization of the enterprise during the epidemic, and expressed his gratitude to Daye City and Baoan Town for their help to Daye Peak during this period. Mayor Zhou Jun spoke highly of the production and technological transformation organization during the Daye peak epidemic, believing that this is a model of combining epidemic prevention and control with enterprise production and technological transformation organization. At the same time, Zhou Jun expressed his affirmation and gratitude to Daye Peak for donating money and goods to Daye City in the first time after the outbreak of the epidemic, and issued a donation certificate and a letter of thanks on behalf of the Daye City Charity Federation. Hubei Province epidemic prevention and control headquarters has recently issued a step-by-step "unsealing" notice in Hubei Province, how to fully resume work and production as soon as possible is an important issue facing Daye peak. Zhang Fengliang reported to Zhou Jun and his party on the current practical difficulties. Mayor Zhou Jun asked
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-30